• Type 2 diabetes mellitus (as an adjunct to diet and exercise).

Contraindicated in:

• Hypersensitivity
• Type 1 diabetes mellitus.

Use Cautiously in:

• Renal impairment (↓ dose for CCr <45 mL/min)
• History of pancreatitis
• History of angioedema to another DPP-4 inhibitor
• History of HF or renal impairment (↑ risk of HF)
• OB: Safety not established in pregnancy; Lactation: Safety not established in breastfeeding
• Pedi: Safety and effectiveness not established in children
• Geri: Consider age-related ↓ in renal function when determining dose in older adults.

CV: HF.

Derm: bullous pemphigoid, rash, STEVENS-JOHNSON SYNDROME (SJS), urticaria.

EENT: nasopharyngitis.

GI: diarrhea, nausea, PANCREATITIS.

GU: acute renal failure.

MS: arthralgia, back pain, myalgia, RHABDOMYOLYSIS.

Neuro: headache.

Resp: upper respiratory tract infection.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Drug-Drug:

• May slightly ↑ levels of digoxin; monitoring recommended.
• ↑risk of hypoglycemia when used with insulin, glyburide, glipizide, or glimepiride; may need to ↓ dose of insulin or sulfonylurea.

• Tablets: 25 mg; 50 mg; 100 mg;
• In combination with: ertugliflozin (Steglujan); metformin (Janumet); metformin XR (Janumet XR). See Appendix [not included in this PDA edition].

• PO (Adults): 100 mg once daily.

Januvia

• Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which slows the inactivation of incretin hormones, resulting in increased levels of active incretin hormones. These hormones are released by the intestine throughout the day and are involved in regulation of glucose homeostasis. Increased/prolonged incretin levels result in an increase in insulin release and decrease in glucagon levels.

• Improved control of blood glucose.

Therapeutic Classification: antidiabetics

Pharmacologic Classification: enzyme inhibitors

Absorption: 87% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Undergoes minor metabolism by the liver via the CYP3A4 and CYP2C8 isoenzymes to inactive metabolites; 87% excreted in the urine (79% as unchanged drug), with 13% excreted in the feces.

Half-life: 12.4 hr.

(plasma concentrations)

• Instruct patient to take sitagliptin as directed. Take missed doses as soon as remembered, unless it is almost time for next dose; do not double doses. Advise patient to read the Medication Guide before starting and with each Rx refill in case of changes.
• Explain to patient that sitagliptin helps control hyperglycemia but does not cure diabetes. Therapy is usually long term.
• Instruct patient not to share this medication with others, even if they have the same symptoms; it may harm them.
• Encourage patient to follow prescribed diet, medication, and exercise regimen to prevent hyperglycemic or hypoglycemic episodes.
• Review signs of hypoglycemia and hyperglycemia with patient. If hypoglycemia occurs, advise patient to take a glass of orange juice or 2–3 tsp of sugar, honey, or corn syrup dissolved in water, and notify health care professional.
• Instruct patient in proper testing of blood glucose and urine ketones. These tests should be monitored closely during periods of stress or illness and health care professional notified if significant changes occur.
• Advise patient to stop taking sitagliptin and notify health care professional promptly if symptoms of hypersensitivity reactions (rash; hives; swelling of face, lips, tongue, and throat; difficulty in breathing or swallowing) or pancreatitis occur.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Advise females with reproductive potential to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

sit-a-GLIP-tin